IRIS
PAOLICELLI, DAMIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.670
AS - Asia 3.557
EU - Europa 3.128
SA - Sud America 994
Continente sconosciuto - Info sul continente non disponibili 514
AF - Africa 265
OC - Oceania 9
Totale 17.137
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.494
SG - Singapore 1.368
IT - Italia 1.141
CN - Cina 807
BR - Brasile 769
HK - Hong Kong 465
RU - Federazione Russa 395
SE - Svezia 385
VN - Vietnam 304
DE - Germania 248
FR - Francia 224
GB - Regno Unito 194
FI - Finlandia 164
UA - Ucraina 119
IN - India 110
CI - Costa d'Avorio 109
BD - Bangladesh 107
CA - Canada 84
AR - Argentina 79
ID - Indonesia 64
NL - Olanda 57
JP - Giappone 53
ZA - Sudafrica 44
IQ - Iraq 43
MX - Messico 43
BE - Belgio 41
PK - Pakistan 38
VE - Venezuela 37
TR - Turchia 36
CO - Colombia 32
EC - Ecuador 32
ES - Italia 27
PL - Polonia 27
SA - Arabia Saudita 27
AT - Austria 23
PH - Filippine 23
TN - Tunisia 22
UZ - Uzbekistan 19
MA - Marocco 18
CL - Cile 15
RO - Romania 14
EG - Egitto 13
JM - Giamaica 12
JO - Giordania 11
KE - Kenya 11
AE - Emirati Arabi Uniti 10
LT - Lituania 10
CR - Costa Rica 9
MY - Malesia 9
PY - Paraguay 9
UY - Uruguay 9
AU - Australia 8
CZ - Repubblica Ceca 8
ET - Etiopia 8
OM - Oman 8
AZ - Azerbaigian 7
DZ - Algeria 7
IR - Iran 7
KZ - Kazakistan 7
NP - Nepal 7
PA - Panama 7
SN - Senegal 7
AL - Albania 6
BO - Bolivia 6
DO - Repubblica Dominicana 6
IE - Irlanda 6
PE - Perù 6
BG - Bulgaria 5
KG - Kirghizistan 5
PS - Palestinian Territory 5
PT - Portogallo 5
CH - Svizzera 4
EU - Europa 4
HU - Ungheria 4
IL - Israele 4
NG - Nigeria 4
DK - Danimarca 3
GR - Grecia 3
HR - Croazia 3
SC - Seychelles 3
A1 - Anonimo 2
AO - Angola 2
BB - Barbados 2
BS - Bahamas 2
GT - Guatemala 2
HN - Honduras 2
KR - Corea 2
LB - Libano 2
MD - Moldavia 2
MK - Macedonia 2
MZ - Mozambico 2
NI - Nicaragua 2
PR - Porto Rico 2
RS - Serbia 2
RW - Ruanda 2
SV - El Salvador 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BF - Burkina Faso 1
BH - Bahrain 1
Totale 16.604
Salva come PNG Salva come JPEG
Città #
Fairfield 893
Ashburn 872
Singapore 726
Woodbridge 603
Chandler 514
San Jose 512
Hong Kong 464
Houston 429
Seattle 402
Milan 368
Cambridge 315
Wilmington 307
Nyköping 290
Beijing 261
Jacksonville 226
Ann Arbor 224
Council Bluffs 224
Dallas 184
New York 147
Lauterbourg 139
Los Angeles 124
Bari 119
Lawrence 118
Rome 117
Roxbury 114
Abidjan 109
Ho Chi Minh City 97
Boardman 95
Nanjing 94
Helsinki 75
Des Moines 73
Santa Clara 73
Princeton 68
Brooklyn 63
Buffalo 59
Columbus 59
Chicago 55
Munich 55
São Paulo 55
Hanoi 51
Tokyo 51
Inglewood 49
London 43
Brussels 40
Moscow 40
San Diego 39
Frankfurt am Main 37
Jakarta 36
Orem 35
Falkenstein 34
Nuremberg 33
Toronto 29
Rio de Janeiro 28
Turin 27
Figino 25
Montreal 25
Nanchang 25
Atlanta 24
Shenyang 24
Amsterdam 23
Guangzhou 22
Johannesburg 22
Phoenix 22
San Francisco 22
Norwalk 21
Warsaw 21
Belo Horizonte 20
Denver 20
Dong Ket 20
Baghdad 18
Tianjin 18
Caracas 17
Chennai 17
Hebei 17
Jiaxing 17
Paris 17
Shanghai 15
Stockholm 15
Haiphong 14
Lahore 14
Poplar 14
Tashkent 14
Bisceglie 13
Boston 13
Brasília 13
Dhaka 13
Buenos Aires 12
Marseille 12
Miami 12
North Bergen 12
Palermo 12
Salt Lake City 12
Wuhan 12
Bologna 11
Cagliari 11
Da Nang 11
Guayaquil 11
Jeddah 11
Manchester 11
Medellín 11
Totale 11.050
Salva come PNG Salva come JPEG
Nome #
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study 235
Signs and symptoms of COVID-19 in patients with multiple sclerosis 224
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 214
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 208
Prognostic indicators in pediatric clinically isolated syndrome 192
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta 190
A rare association between multiple sclerosis and Charcot-Marie-Tooth type 1B 190
Age-related changes of serum N-acetyl-aspartate in healthy controls. 189
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 187
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 185
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 184
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta 183
"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study 177
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 175
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients 171
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 171
Age-related disability in multiple sclerosis 169
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy 163
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 160
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 155
Analisi longitudinale dei livelli sierici di ICAM-1 solubile e dei subsets di linfociti T in pazienti con Sclerosi Multipla a decorso remittente in trattamento con IFNb-1b 155
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study 153
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis 152
PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels 148
BLOOD MMP-9 AND SICAM-1 AS MARKERS OF RIFN-B TREATMENT EFFICACY IN RELAPSING-REMITTING MS 147
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 142
Multiple Sclerosis Progression and Relapse Activity in Children 141
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 140
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. 137
A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study. 135
Atypical forms of Multiple Sclerosis or different phases of a same disease? 132
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 132
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years 130
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France 129
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. 128
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) 128
Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis 128
ADHESION MOLECULES AND MATRIX METALLOPROTEINASES IN MS: EFFECTS INDUCED BY INTERFERON BETA 125
Patient expression of emotions and neurologist responses in first multiple sclerosis consultations 124
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method 124
Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience 124
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study 123
Geographical variations in sex ratio trends over time in multiple sclerosis. 123
Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review 123
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. 122
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 122
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 122
Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients 121
Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. 120
Low serum urate levels are associated to female gender in multiple sclerosis patients. 120
Effect of cladribine on neuronal apoptosis: New insight of in vitro study in multiple sclerosis therapy 120
Magnetoencephalography and high‐density electroencephalography study of acoustic event related potentials in early stage of multiple sclerosis: A pilot study on cognitive impairment and fatigue 119
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study 118
Predictors of disability worsening in clinically isolated syndrome 117
A nurse-led, telephone-based patient support program for improving adherence in patients with relapsing-remitting multiple sclerosis using interferon beta-1a: Lessons from a consumer-based survey on adveva® PSP 116
Durvalumab and multiple sclerosis: a causal link or simple unmasking? 116
Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients 115
Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. 113
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 113
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. 112
Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? 111
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing 110
null 109
The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. 109
Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study 108
Postmarketing evidence of disease-modifying drugs in multiple sclerosis 107
CHANGES OF SERUM ICAM-1 AND MMP-9 INDUCED BY RIFNB-1B TREATMENT IN RELAPSING-REMITTING MS 104
Variations of the perforin gene in patients with multiple sclerosis. 103
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. 102
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors 102
Macular ganglion cell-inner plexiform layer defect patterns in multiple sclerosis patients without optic neuritis: A Spectral-Domain-Optical Coherence Tomography Cross-Sectional, Case-Control, Pilot Study 101
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study 101
Impact of depression on the perception of fatigue and information processing speed in a cohort of multiple sclerosis patients 100
A case report of late-onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review 98
Coverage of the requirements of first and second level stroke unit in Italy 97
Informing MS patients on treatment options: a consensus on the process of consent taking 95
Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy 93
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks 92
RIFNB DOWNREGULATES TNFA-INDUCED ICAM-1 EXPRESSION ON BRAIN MICROVASCULAR ENDOTHELIAL CELLS (BEMC) AND INCREASES SERUM SOLUBLE ICAM-1 (SICAM-1) IN RR MS 91
Modificazioni dei livelli sierici di ICAM-1 solubile (sICAM.1), e Gelatinasi A e B e sottopopolazioni T-linfocitarie di sangue periferico indotte dal trattamento con interferone-beta-1b (IFN-BETA-1B) in pazienti con Sclerosi Multipla (SM) Relapsing-Remitting (RR): Relazione con la produzione di anticorpi neutralizzanti anti-interferone (NABs) 91
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks 90
Acoustic Voice Analysis as a Useful Tool to Discriminate Different ALS Phenotypes 90
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis 89
CHANGES OF SERUM SOLUBLE ICAM-1 AND MATRIX METALLOPROTEINASE-9 DURING INTERFERON BETA-1B TREATMENT IN RR MS 89
Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study 89
The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. 89
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group 89
Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study) 89
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis 87
Enhancement is an age-related feature of multiple sclerosis lesions 87
The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes. 87
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 87
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: A 18-month multicentre study 86
An Internet- and Kinect-Based Multiple Sclerosis Fitness Intervention Training With Pilates Exercises: Development and Usability Study 85
Immunomodulatory therapies delay disease progression in multiple sclerosis. 83
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. 82
A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia 81
The IFN beta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy 81
The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study. 81
Mitochondria, Oxidative Stress, cAMP Signalling and Apoptosis: A Crossroads in Lymphocytes of Multiple Sclerosis, a Possible Role of Nutraceutics 80
Totale 12.576
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.122
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.122
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022770 0 0 16 33 44 88 43 46 86 59 173 182
2022/20231.382 225 178 83 122 162 162 17 165 204 5 26 33
2023/2024461 57 66 28 29 37 108 13 18 8 23 6 68
2024/20252.782 133 42 180 102 75 246 257 223 133 166 424 801
2025/20266.424 842 357 436 736 652 360 642 213 664 593 222 707
2026/2027666 217 277 172 0 0 0 0 0 0 0 0 0
Totale 17.137